Neurocrine Bio. (NBIX) Bullish Stance Reiterated at Cowen

Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results

Leerink Partners reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX), and raised the price target to $71.00 (from $67.00), following positive KINECT3 results. Analyst Paul Matteis We sees the likelihood of the emergence of an unexpected long-term safety signal as very low, but still possible given the patient population under surveillance.

Matteis commented, "On the heels of positive... More

Neurocrine Bio. (NBIX) PT Bumped to $66 at Baird on NBI-98854 Phase 3 Success

Baird analyst Brian Skorney reiterated an Outperform rating and bumped his price target on Neurocrine Bio. (NASDAQ: NBIX) to $66.00 (from $64.00) saying the Phase 3 success gives them confidence in the outlook.

Skorney commented, "NBI-98854's success in Phase 3 makes the path towards approval... More

Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray

Piper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).

Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More

Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia

Neurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More